Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01185 (vasopressin)
 23,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A moderate elevation of the daily excretion of free noradrenaline and adrenalin is observed in chronic circulatory insufficiency, beginning with Stage IIA. The catecholamines metabolism is elevated, as shown by the daily excretion of normethanpherine and methanpherine and of vanillyl-mandelic acid. The activity of renin and angiotensinases was growing along with the progressing cardiac insufficiency. The blood level of angiotensinogen was decreasing, especially in patients with Stage IIB and III of decompensation. The daily excretion of aldosterone was growing along with the development of cardiac insufficiency. The functional state of the glucocorticoid function of the adrenal cortex was of a phased nature in cases of circulatory insufficiency. The study of the functional state of the epiphysis was conducted by way of determining the blood level of melatonine and of its daily excretion. In Stages I and IIA the level of this hormone was clearly elevated, in Stages IIB and III -- decreased as compared with the initial and normal levels. The plasma level of the antidiuretic hormone was distinctly growing, beginning with Stage IIB, reaching its maximal values in Stage III.
 ...
PMID:[State of the neurohumoral regulatory system in circulatory insufficiency]. 18 17

Experiments on dogs demonstrated that intravenous administration of the epiphysis extracts prevented the antidiuretic action of both the endogenous (traumatic stress) and exogenous (pituitrin) antidiuretic hormone (ADH). Injection of the extract into the renal artery gave a unilateral diuretic effect. The diuretic action of the preparation was eliminated by the block of the alpha-adrenergic receptors, whereas beta-adrenoblockers were ineffective. A conclusion was drawn that the mechanism of the diuretic action of the epiphysis extracts consisted in the competitive suppression of the ADH action at the renal tubules level on account of excitation of the alpha-adrenoceptors and inhibition of the adenylcyclase activity.
 ...
PMID:[Mechanism of the diuretic action of epiphyseal extracts]. 21 86

The object of the study was to determine the possibility of using myelopid in correction of the functional condition of the melatonin-opioid and the hypothalamo-hypophyseal-adrenal systems and of the activity of the neurohypophysis in traumatic toxicosis. It was demonstrated in rat experiments that in traumatic toxicosis myelopid modulates synthesis of neuropeptides (melatonin, corticoliberin) and their release into blood plasma. By reducing the blood plasma vasopressin content, myelopid promotes increase in the corticoliberin content in the hypothalamus and increase of 11-OCS biosynthesis in the adrenals. At the same time, the agent increases the melatonin content in the epiphysis cerebri of intact animals and in rats with traumatic toxicosis and reduces the content of leuenkephalin in blood plasma. The role of myelopid in correction of neuroendocrine disorders in traumatic toxicosis is discussed.
 ...
PMID:[Management of neuroendocrine disorders in traumatic toxicosis using mielopid]. 216 71

Human growth hormone is, in effect, defined by its activity in an in vivo bioassay and the standard used with it, growth being measured as the increase in body weight in hypophysectomised immature rats. The assay reflects the hormone's survival and metabolism in vivo, its cell-cell interactions, the activation and effects of its secondary hormones, such as GF1 and GF2, and various feedback mechanisms. Although it is insensitive, imprecise, easily influenced by contaminants TSH and vasopressin, it is the only practical assay that reflects all the in vivo properties of "hGH". The in vivo tibial epiphysis bioassay is more sensitive and precise, but the response reflects only the elongation of bone. Both these bioassays are well established. By contrast, in vitro receptor assays do not reflect in vivo properties; there may be different natural forms of receptor molecules, they may be altered during their extraction, and the measured response (like those of immunoassays) is not relevant to the biological action of the hormone. The validity of a bioassay depends on the use of a suitable standard. The collaborative study of the International Standard for human growth hormone (in 1984) revealed marked disparities between results with different assay methods. When a growth hormone protein (such as somatotropin, 191 amino acids) is produced in quantity, reproducibly, and with physicochemical properties consistently related to in vivo bioassay results, it may then be reasonable to use physico-chemical tests for control purposes. Many such tests require international reference materials for comparison purposes.
 ...
PMID:Assays for human growth hormones. 248 17